secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0000950170-25-095167
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm cuts workforce 20%, explores strategic alternatives including sale
-----------------------------------------------------------------------------

- Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.
- Board evaluating financing, merger/sale, restructuring, or debt refinancing; no deal yet.
- Engaged with potential investors under confidentiality; discussions did not result in a transaction.
- Committed to Phase 3 trials in myelofibrosis and endometrial cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/0000950170-25-095167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/kpti-20250711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-095167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer